Predictive factors of vascular complications after transcatheter aortic valve implantation in patients treated with a default percutaneous strategy

Cardiovascular Therapeutics

Volumn 31, Issue 5, 2013, Pages

  Vavuranakis, Manolis ^a   Kariori, Maria ^a   Voudris, Vassilis ^b   Kalogeras, Konstantinos ^a   Vrachatis, Dimitrios ^a   Aznaouridis, Constantinos ^a   Moldovan, Carmen ^a   Masoura, Constantina ^a   Thomopoulou, Sophia ^b   Lazaros, Georgios ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

Predictive factors; Prostar closure device; TAVI; Vascular complications

Indexed keywords

CREATININE;

AGED; AORTA DISSECTION; AORTA PERFORATION; AORTOGRAPHY; ARTERY CALCIFICATION; ARTICLE; ATHEROMATOSIS; CARDIOVASCULAR EQUIPMENT; CREATININE CLEARANCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RETROPERITONEAL HEMATOMA; RETROSPECTIVE STUDY; TRANSCATHETER AORTIC VALVE IMPLANTATION; VASCULAR CLOSURE DEVICE; VASCULAR DISEASE;

PREDICTIVE FACTORS; PROSTAR CLOSURE DEVICE; TAVI; VASCULAR COMPLICATIONS;

AGED; AGED, 80 AND OVER; AORTIC VALVE; CARDIAC CATHETERIZATION; FEMALE; FEMORAL ARTERY; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; STENTS; VASCULAR CALCIFICATION;

EID: 84883799136     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12023     Document Type: Article

References (39)

1. Gerckens U, Cattelaens N, Lampe EG, Grube E. Management of arterial puncture site after catheterization procedures: evaluating a suture-mediated closure device. Am J Cardiol 1999;83:1658-1663.
2. Carere RG, Webb JG, Ahmed T, Dodek AA. Initial experience using Prostar: a new device for percutaneous suture-mediated closure of arterial puncture sites. Cathet Cardiovasc Diagn 1996;37:367-372.
3. Bechara CF, Annambhotla S, Lin PH. Access site management with vascular closure devices for percutaneous transarterial procedures. J Vasc Surg 2010;52:1682-1696.
4. Vergnat M, Finet G, Rioufol G, Obadia JF. Percutaneous femoral artery access with Prostar device for innovative mitral and aortic interventions. Eur J Cardiothorac Surg 2011;39:600-602.
5. Hayashida K, Lefevre T, Chevalier B, Hovasse T, Romano M, Garot P, et al. Transfemoral aortic valve implantation new criteria to predict vascular complications. JACC Cardiovasc Interv 2011;4:851-858.
6. Gonze MD, Sternbergh WC 3rd, Salartash K, Money SR. Complications associated with percutaneous closure devices. Am J Surg 1999;178:209-211.
7. Haas PC, Krajcer Z, Diethrich EB. Closure of large percutaneous access sites using the Prostar XL Percutaneous Vascular Surgery device. J Endovascu Surg 1999;6:168-170.
8. Masson JB, Kovac J, Schuler G, Ye J, Cheung A, Kapadia S, et al. Transcatheter aortic valve implantation: review of the nature, management, and avoidance of procedural complications. JACC Cardiovasc Interv 2009;2:811-820.
9. Kahlert P, Al-Rashid F, Weber M, Wendt D, Heine T, Kottenberg E, et al. Vascular access site complications after percutaneous transfemoral aortic valve implantation. Herz 2009;34:398-408.
10. Vavuranakis M, Voudris V, Vrachatis DA, Thomopoulou S, Toutouzas K, Karavolias G, et al. Transcatheter aortic valve implantation, patient selection process and procedure: two centres' experience of the intervention without general anaesthesia. Hellenic J Cardiol 2010a;51:492-500.
11. Vassiliades TA Jr, Block PC, Cohn LH, Adams DH, Borer JS, Feldman T, et al. The clinical development of percutaneous heart valve technology: a position statement of the Society of Thoracic Surgeons (STS), the American Association for Thoracic Surgery (AATS), and the Society for Cardiovascular Angiography and Interventions (SCAI) Endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA). J Am Coll Cardiol 2005;45:1554-1560.
12. Eltchaninoff H, Kerkeni M, Zajarias A, Tron C, Godin M, Sanchez Giron C, et al. Aorto-iliac angiography as a screening tool in selecting patients for transfemoral aortic valve implantation with the Edwards SAPIEN bioprosthesis. EuroIntervention. 2009;5:438-442.
13. Nietlispach F, Leipsic J, Al-Bugami S, Masson JB, Carere RG, Webb JG. CT of the ilio-femoral arteries using direct aortic contrast injection: proof of feasibility in patients screened towards percutaneous aortic valve replacement. Swiss Med Wkly 2009;139:458-462.
14. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J 2011;32:205-217.
15. Baim DS, Knopf WD, Hinohara T, Schwarten DE, Schatz RA, Pinkerton CA, et al. Suture-mediated closure of the femoral access site after cardiac catheterization: results of the suture to ambulate aNd discharge (STAND I and STAND II) trials. Am J Cardiol 2000;85:864-869.
16. Genereux P, Kodali S, Leon MB, Smith CR, Ben-Gal Y, Kirtane AJ, et al. Clinical outcomes using a new crossover balloon occlusion technique for percutaneous closure after transfemoral aortic valve implantation. JACC Cardiovasc Interv 2011;4:861-867.
17. Sherif MA, Abdel-Wahab M, Stocker B, Geist V, Richardt D, Tolg R, et al. Anatomic and procedural predictors of paravalvular aortic regurgitation after implantation of the Medtronic CoreValve bioprosthesis. J Am Coll Cardiol 2010;56:1623-1629.
18. Vavouranakis M, Vrachatis DA, Toutouzas KP, Chrysohoou C, Stefanadis C. "Bail out" procedures for malpositioning of aortic valve prosthesis (CoreValve). Int J Cardiol 2010;145:154-155.
19. Vavuranakis M, Vrachatis D, Stefanadis C. CoreValve aortic bioprosthesis: repositioning techniques. JACC Cardiovasc Interv. 2010b;3:565; author reply -6.
20. Ducrocq G, Francis F, Serfaty JM, Himbert D, Maury JM, Pasi N, et al. Vascular complications of transfemoral aortic valve implantation with the Edwards SAPIEN prosthesis: incidence and impact on outcome. EuroIntervention 2010;5:666-672.
21. Thomas M, Schymik G, Walther T, Himbert D, Lefevre T, Treede H, et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010;122:62-69.
22. Tchetche D, Dumonteil N, Sauguet A, Descoutures F, Luz A, Garcia O, et al. Thirty-day outcome and vascular complications after transarterial aortic valve implantation using both Edwards Sapien and Medtronic CoreValve bioprostheses in a mixed population. EuroIntervention 2010;5:659-665.
23. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-1607.
24. Lefevre T, Kappetein AP, Wolner E, Nataf P, Thomas M, Schachinger V, et al. One year follow-up of the multi-centre European PARTNER transcatheter heart valve study. Eur Heart J 2011;32:148-157.
25. Rodes-Cabau J, Webb JG, Cheung A, Ye J, Dumont E, Feindel CM, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 2010;55:1080-1090.
26. Piazza N, Grube E, Gerckens U, den Heijer P, Linke A, Luha O, et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention 2008;4:242-249.
27. Van Mieghem NM, Nuis RJ, Piazza N, Apostolos T, Ligthart J, Schultz C, et al. Vascular complications with transcatheter aortic valve implantation using the 18 Fr Medtronic CoreValve System: the Rotterdam experience. EuroIntervention 2010;5:673-679.
28. Webb JG, Altwegg L, Boone RH, Cheung A, Ye J, Lichtenstein S, et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation 2009;119:3009-3016.
29. Bleiziffer S, Ruge H, Mazzitelli D, Hutter A, Opitz A, Bauernschmitt R, et al. Survival after transapical and transfemoral aortic valve implantation: talking about two different patient populations. J Thorac Cardiovasc Surg 2009;138:1073-1080.
30. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium-2 consensus document. J Am Coll Cardiol 2012;60:1438-1454.
31. Troianos CA, Hartman GS, Glas KE, Skubas NJ, Eberhardt RT, Walker JD, et al. Guidelines for performing ultrasound guided vascular cannulation: recommendations of the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr 2011;24:1291-1318.
32. Seto AH, Abu-Fadel MS, Sparling JM, Zacharias SJ, Daly TS, Harrison AT, et al. Real-time ultrasound guidance facilitates femoral arterial access and reduces vascular complications: FAUST (Femoral Arterial Access With Ultrasound Trial). JACC Cardiovasc Interv 2010;3:751-758.
33. Sharp AS, Michev I, Maisano F, Taramasso M, Godino C, Latib A, et al. A new technique for vascular access management in transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2010;75:784-793.
34. Ferrari E, von Segesser LK. Transcatheter aortic valve implantation (TAVI): state of the art techniques and future perspectives. Swiss Med Wkly 2010;140:w13127.
35. Nuis RJ, Van Mieghem NM, Tzikas A, Piazza N, Otten AM, Cheng J, et al. Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2011;77:881-889.
36. Bagur R, Webb JG, Nietlispach F, Dumont E, De Larochelliere R, Doyle D, et al. Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement. Eur Heart J 2010;31:865-874.
37. Franco CD, Goldsmith J, Veith FJ, Calligaro KD, Gupta SK, Wengerter KR. Management of arterial injuries produced by percutaneous femoral procedures. Surgery 1993;113:419-425.
38. Samal AK, White CJ. Percutaneous management of access site complications. Catheter Cardiovasc Interv 2002;57:12-23.
39. Tsetis D. Endovascular treatment of complications of femoral arterial access. Cardiovasc Intervent Radiol 2010;33:457-468.